## **Daniel Taussky**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/127945/publications.pdf

Version: 2024-02-01

713013 686830 61 536 13 21 citations h-index g-index papers 61 61 61 939 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas. Head and Neck, 2005, 27, 182-186.	0.9	73
2	Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer, 2015, 15, 594.	1.1	49
3	Urethra-Sparing, Intraoperative, Real-Time Planned, Permanent-Seed Prostate Brachytherapy: Toxicity Analysis. International Journal of Radiation Oncology Biology Physics, 2011, 81, e377-e383.	0.4	32
4	Twitter. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 442-445.	0.6	24
5	Seed migration in prostate brachytherapy depends on experience and technique. Brachytherapy, 2012, 11, 452-456.	0.2	23
6	A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer. Advances in Radiation Oncology, 2019, 4, 631-640.	0.6	21
7	Influence of abdominal adiposity, waist circumference, and body mass index on clinical and pathologic findings in patients treated with radiotherapy for localized prostate cancer. Cancer, 2010, 116, 5650-5658.	2.0	18
8	Magnetic resonance imaging for prostate bed radiotherapy planning: An inter―and intraâ€observer variability study. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 255-259.	0.9	18
9	Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. Radiation Oncology, 2019, 14, 60.	1.2	18
10	External Beam Radiotherapy Affects Serum Testosterone in Patients with Localized Prostate Cancer. Journal of Sexual Medicine, 2017, 14, 876-882.	0.3	16
11	Bone marrow-sparing intensity-modulated radiation therapy for Stage I seminoma. Acta Oncol $ ilde{A}^3$ gica, 2011, 50, 555-562.	0.8	14
12	Preoperative Intensity Modulated Radiation Therapy for Retroperitoneal Sarcoma. Technology in Cancer Research and Treatment, 2014, 13, 211-216.	0.8	14
13	Risk factors for developing a second upper aerodigestive cancer after radiotherapy with or without chemotherapy in patients with head-and-neck cancers: An exploratory outcomes analysis.  International Journal of Radiation Oncology Biology Physics, 2005, 62, 684-689.	0.4	13
14	The <scp>C</scp> ancer of the <scp>P</scp> rostate <scp>R</scp> isk <scp>A</scp> ssessment ( <scp>CAPRA</scp> ) score predicts biochemical recurrence in intermediateâ€risk prostate cancer treated with external beam radiotherapy ( <scp>EBRT</scp> ) dose escalation or lowâ€dose rate ( <scp>LDR</scp> ) brachytherapy. BJU International, 2014, 114, 865-871.	1.3	13
15	Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. Canadian Urological Association Journal, 2020, 15, 181-186.	0.3	13
16	Analysis of the Cancer of the Prostate Risk Assessment to Predict for Biochemical Failure After External Beam Radiotherapy or Prostate Seed Brachytherapy. Urology, 2014, 84, 629-633.	0.5	12
17	Does Timing of Androgen Deprivation Influence Radiation-Induced Toxicity? A Secondary Analysis of Radiation Therapy Oncology Group Protocol 9413. Urology, 2008, 72, 1125-1129.	0.5	11
18	PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study. Brachytherapy, 2021, 20, 1090-1098.	0.2	10

#	Article	IF	CITATIONS
19	A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer. Canadian Urological Association Journal, 2016, 10, 246.	0.3	9
20	Favorable preservation of erectile function after prostate brachytherapy for localized prostate cancer. Brachytherapy, 2020, 19, 222-227.	0.2	9
21	Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience. Cureus, 2016, 8, e935.	0.2	9
22	Impact of adipose tissue on prostate cancer aggressiveness – analysis of a high-risk population. Hormone Molecular Biology and Clinical Investigation, 2018, 36, .	0.3	8
23	Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database. Canadian Journal of Urology, 2018, 25, 9509-9515.	0.0	8
24	Influence of body mass index and periprostatic fat on rectal dosimetry in permanent seed prostate brachytherapy. Radiation Oncology, 2014, 9, 93.	1.2	7
25	Is intraoperative real-time dosimetry in prostate seed brachytherapy predictive of biochemical outcome?. Journal of Contemporary Brachytherapy, 2017, 4, 304-308.	0.4	7
26	The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 57.e15-57.e23.	0.8	7
27	Refining prostate seed brachytherapy: Comparing high-, intermediate-, and low-activity seeds for I-125 permanent seed prostate brachytherapy. Brachytherapy, 2015, 14, 329-333.	0.2	6
28	Impact of visceral fat volume and fat density on biochemical outcome after radical prostatectomy and postoperative radiotherapy. Hormone Molecular Biology and Clinical Investigation, 2016, 26, 173-178.	0.3	6
29	Seed loss in prostate brachytherapy. Strahlentherapie Und Onkologie, 2016, 192, 305-311.	1.0	6
30	A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer. Targeted Oncology, 2017, 12, 695-701.	1.7	6
31	The Quadrella: A novel approach to analyzing optimal outcomes after permanent seed prostate brachytherapy. Radiotherapy and Oncology, 2014, 111, 110-113.	0.3	5
32	A comparison of early prostate-specific antigen decline between prostate brachytherapy and different fractionation of external beam radiation‒Impact on biochemical failure. Brachytherapy, 2018, 17, 277-282.	0.2	5
33	Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect?. Canadian Journal of Urology, 2009, 16, 4599-600.	0.0	5
34	Prostate-specific antigen density is predictive of outcome in suboptimal prostate seed brachytherapy. Brachytherapy, 2017, 16, 348-352.	0.2	4
35	Pelvic radiotherapy in prostate cancer: an unresolved question. Lancet Oncology, The, 2018, 19, 1428-1429.	5.1	4
36	CAPRA-S predicts outcome for adjuvant and salvage EBRT after radical prostatectomy. Canadian Urological Association Journal, 2016, 10, 132.	0.3	4

#	Article	lF	Citations
37	The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology, 2012, 36, e137-e141.	0.8	3
38	Radiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices. Canadian Urological Association Journal, 2015, 9, 608.	0.3	3
39	Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy. World Journal of Urology, 2021, 39, 4127-4133.	1.2	3
40	A Portrait of Current Radiation Oncology Twitter Influencers. Cureus, 2020, 12, e10838.	0.2	3
41	A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer. Canadian Urological Association Journal, 2022, 16, .	0.3	3
42	Risk factors for biochemical recurrence after a tissue-ablative prostate-specific antigen <0.2Âng/mL. Brachytherapy, 2018, 17, 794-798.	0.2	2
43	Do Women Have Equal Chances for an Academic Career in Radiation Oncology in Canada? A Comparison With Related Specialties. Advances in Radiation Oncology, 2020, 5, 313-317.	0.6	2
44	Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate. Cells, 2020, 9, 2153.	1.8	2
45	Is pelvic prophylactic radiotherapy in prostate cancer just right?. Translational Andrology and Urology, 2020, 9, 2296-2298.	0.6	2
46	Functional and oncological outcomes of salvage external beam radiotherapy following robot-assisted radical prostatectomy in a Canadian cohort. Canadian Urological Association Journal, 2017, 12, 45-9.	0.3	1
47	Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. Canadian Urological Association Journal, 2019, 14, E173-E179.	0.3	1
48	Impact of diabetes and metformin use on prostate cancer. Scandinavian Journal of Urology, 2020, 54, 508-509.	0.6	1
49	The relationship between preâ€radiation therapy testosterone levels and prostate cancer aggressiveness. Andrologia, 2020, 52, e13731.	1.0	1
50	The interaction between inflammation, urinary symptoms and erectile dysfunction in earlyâ€stage prostate cancer treated with brachytherapy. Andrologia, 2021, 53, e14070.	1.0	1
51	The one hundred most cited publications in prostate brachytherapy. Brachytherapy, 2021, 20, 611-623.	0.2	1
52	Authors' response. Brachytherapy, 2017, 16, 655.	0.2	0
53	External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. Canadian Urological Association Journal, 2017, 11, 94.	0.3	0
54	Pre-radiotherapy PSA progression is aÂnegative prognostic factor in prostate cancer patients using 5â€'alpha-reductase inhibitors. Strahlentherapie Und Onkologie, 2018, 194, 17-22.	1.0	0

#	Article	IF	CITATIONS
55	Active surveillance before radiotherapy — outcome and predictive factors for multiple biopsies before treatment. Canadian Urological Association Journal, 2020, 15, E36-E40.	0.3	0
56	Association of neutrophil count with overall survival in localized prostate cancer Journal of Clinical Oncology, 2015, 33, 121-121.	0.8	0
57	Pre-treatment PSA- progression as a negative prognostic factor in patients using 5-alpha-reductase inhibitors prior to radiotherapy for prostate cancer Journal of Clinical Oncology, 2017, 35, 96-96.	0.8	0
58	Fusion of Intraoperative Transrectal Ultrasound Images with Post-implant Computed Tomography and Magnetic Resonance Imaging. Cureus, 2018, 10, e2394.	0.2	0
59	Prevalence and Risk Factors of QTc Prolongation in Prostate Cancer Patients Undergoing Brachytherapy. Cancer Investigation, 2022, , 1-9.	0.6	0
60	Postoperative radiotherapy after prostatectomy: whom to treat. Finally light at the end of the tunnel?. Canadian Journal of Urology, 2016, 23, 8576.	0.0	0
61	Biochemical failure-rate and preservation of erectile function after prostate seed brachytherapy in early-onset prostate cancer Canadian Journal of Urology, 2022, 29, 10986-10991.	0.0	0